Dry Eye Disease ( DED)

CSDE

Home Products CSDE

Dry Eye Disease (DED)

With the global aging population, increased use of digital devices, and changes in lifestyle, the number of patients affected by dry eye disease continues to rise. Dry eye disease not only impairs visual quality and daily activities but also imposes a long-term burden on work productivity and healthcare resources. Due to its complex pathophysiology and the need for long-term management in most patients, significant and growing unmet medical needs remain in this field.

Global Dry Eye Disease Population

300 Million+

Estimated global population affected by dry eye disease

5-50 %

Global prevalence of dry eye disease

70 %

Highest reported prevalence among elderly populations

Market Potential

CSDE

Dry Eye Disease

Dry eye disease (DED), also known as dry eye syndrome (DES), is one of the most common chronic ocular surface disorders worldwide. Clinical symptoms include dryness, burning sensation, foreign body sensation, fluctuating vision, and eye fatigue, all of which can significantly affect patients’ quality of life and work productivity. With the rapid aging of the global population and the increasing use of computers and mobile devices, the number of patients suffering from dry eye disease continues to rise, making it one of the most common conditions seen in ophthalmology clinics.

Epidemiological studies show that the prevalence of dry eye disease increases significantly with age, with women and Asian populations considered higher-risk groups. The pathophysiology of DED involves multiple factors, including reduced tear secretion, tear film instability, chronic ocular surface inflammation, and neurosensory abnormalities. These mechanisms often result in a chronic and recurrent disease course requiring long-term management. However, current clinical treatments mainly rely on artificial tears and supportive therapies, which remain limited in addressing the multiple pathological mechanisms of the disease.

In addition, research indicates that dry eye disease is often underdiagnosed and underrecognized, particularly among elderly populations. Many patients receive symptomatic treatment without realizing that they are affected by a chronic condition requiring long-term care, or they may mistakenly believe their symptoms are merely temporary eye fatigue.

Overall, innovative therapeutic strategies that target multiple pathological mechanisms, are suitable for long-term use, and effectively improve patients’ quality of life demonstrate strong market growth potential and represent an important area of investment in ophthalmology.

資料來源：
1.Craig, J. P., Nichols, K. K., Akpek, E. K., Caffery, B., Dua, H. S., Joo, C. K., et al. (2017). TFOS DEWS II definition and classification report. The Ocular Surface, 15(3), 276–283.
2.Stapleton, F., Alves, M., Bunya, V. Y., Jalbert, I., Lekhanont, K., Malet, F., et al. (2017). TFOS DEWS II epidemiology report. The Ocular Surface, 15(3), 334–365.
3.Bron, A. J., de Paiva, C. S., Chauhan, S. K., Bonini, S., Gabison, E. E., Jain, S., et al. (2017). TFOS DEWS II pathophysiology report. The Ocular Surface, 15(3), 438–510.
4.The Definition and Classification Subcommittee of the International Dry Eye WorkShop. (2007). The definition and classification of dry eye disease. The Ocular Surface, 5(2), 75–92.
5.Lin, P. Y., Tsai, S. Y., Cheng, C. Y., Liu, J. H., Chou, P., & Hsu, W. M. (2003). Prevalence of dry eye among an elderly Chinese population in Taiwan: The Shihpai Eye Study. Ophthalmology, 110(6), 1096–1101.
6.National Eye Institute. (2016). Dry eye. National Institutes of Health.

Back to list